Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma

BMC Cancer

Volumn 17, Issue 1, 2017, Pages

  Tsai, Harrison K ^a,c   Lehrer, Jonathan ^b   Alshalalfa, Mohammed ^b   Erho, Nicholas ^b   Davicioni, Elai ^b   Lotan, Tamara L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GenomeDx Biosciences Inc   (Canada)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

FFPE; Gene signature; Meta analysis; Mixed prostatic adenocarcinoma; Nearest centroid classifier; Neuroendocrine prostate cancer; Small cell carcinoma

Indexed keywords

ADENOCARCINOMA; ANALYTICAL ERROR; ARTICLE; CANCER PROGNOSIS; CLASSIFIER; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE COURSE; GENE CLUSTER; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; MIXED TUMOR; NEUROENDOCRINE CARCINOMA; NEUROENDOCRINE PROSTATE CANCER; PHENOTYPE; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; SMALL CELL CARCINOMA; SMALL CELL LUNG CANCER; SMALL CELL PROSTATIC CARCINOMA; TISSUE MICROARRAY; BIOLOGY; CANCER GRADING; CARCINOMA; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC DATABASE; GENETIC HETEROGENEITY; GENETICS; IMMUNOHISTOCHEMISTRY; MALE; META ANALYSIS (TOPIC); PATHOLOGY; PROCEDURES; PROSTATE TUMOR;

TRANSCRIPTOME; TUMOR MARKER;

BIOMARKERS, TUMOR; CARCINOMA, NEUROENDOCRINE; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC HETEROGENEITY; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; META-ANALYSIS AS TOPIC; NEOPLASM GRADING; PROSTATIC NEOPLASMS; TRANSCRIPTOME;

EID: 85033797223     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-017-3729-z     Document Type: Article

References (45)

1. Epstein, JI.,et al., Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol, 2014. 38(6): p. 756-767.
2. Wang HT, et al. Neuroendocrine prostate cancer (nepc) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of nepc and survival from nepc diagnosis-a systematic review and pooled analysis. J Clin Oncol. 2014;32(30):3383-90.
3. Tan, HL, et al., Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin Cancer Res, 2014. 20(4): p. 890-903.
4. Lapuk AV, et al. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol. 2012;227(3):286-97.
5. Yao JL, et al. Small cell carcinoma of the prostate: an immunohistochemical study. Am J surg pathol. 2006;30(6):705-12.
6. Wang W, Epstein JI. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol. 2008;32(1):65-71.
7. Kumar A, et al. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med. 2016;22(4):369-78.
8. Beltran H, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016;22(3):298-305.
9. Roudier MP, et al. Metastatic conventional prostatic adenocarcinoma with diffuse chromogranin a and androgen receptor positivity. J Clin Pathol. 2004;57(3):321-3.
10. Wu C, et al. Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer. J Pathol. 2012;227(1):53-61.
11. Beltran H, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1(6):487-95.
12. Lin D, et al. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res. 2014;74(4):1272-83.
13. Tzelepi V, et al. Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res. 2012;18(3):666-77.
14. Zhang X, et al. Srrm4 expression and the loss of rest activity may promote the emergence of the neuroendocrine phenotype in castration-resistant prostate cancer. Clin Cancer Res. 2015;21(20):4698-708.
15. Hansel DE, et al. Shared tp53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. Prostate. 2009;69(6):603-9.
16. Gravendeel LA, et al. Gene expression profiles of gliomas in formalin-fixed paraffin-embedded material. Br J Cancer. 2012;106(3):538-45.
17. Abdueva D, et al. Quantitative expression profiling in formalin-fixed paraffin-embedded samples by affymetrix microarrays. J Mol Diagn. 2010;12(4):409-17.
18. Hieronymus H, et al. Gene expression signature-based chemical genomic prediction identifies a novel class of hsp90 pathway modulators. Cancer cell. 2006;10(4):321-30.
19. Cuzick J, et al. Prognostic value of an rna expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 2011;12(3):245-55.
20. Ritchie ME, et al. Limma powers differential expression analyses for rna-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):E47.
21. Tsai H, et al. Cyclin d1 loss distinguishes prostatic small-cell carcinoma from most prostatic adenocarcinomas. Clin Cancer Res. 2015;21(24):5619-29.
22. Travis WD. Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas. Mod Pathol. 2012;(25 suppl 1):S18-30.
23. Dalela D, et al. Contemporary role of the decipher(r) test in prostate cancer management: current practice and future perspectives. Rev Urol. 2016;18(1):1-9.
24. Karnes RJ, et al. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol. 2013;190(6):2047-53.
25. Erho N, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. Plos One. 2013;8(6):E66855.
26. Ross AE, et al. Tissue-based genomics augments post-prostatectomy risk stratification in a natural history cohort of intermediate- and high-risk men. Eur Urol. 2016;69(1):157-65.
27. Glass AG, et al. Validation of a genomic classifier for predicting post-prostatectomy recurrence in a community based health care setting. J Urol. 2016;195(6):1748-53.
28. Grasso CS, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487(7406):239-43.
29. Sircar K, et al. Mitosis phase enrichment with identification of mitotic centromere-associated kinesin as a therapeutic target in castration-resistant prostate cancer. Plos One. 2012;7(2):E31259.
30. Yang M, et al. Long noncoding rna cche1 promotes cervical cancer cell proliferation via upregulating pcna. Tumour Biol. 2015;36(10):7615-22.
31. Adler P, et al. Mining for coexpression across hundreds of datasets using novel rank aggregation and visualization methods. Genome biol. 2009;10(12):R139.
32. Haffner MC, et al. Diagnostic challenges of clonal heterogeneity in prostate cancer. J Clin Oncol. 2015;33(7):E38-40.
33. Tan PY, et al. Integration of regulatory networks by nkx3-1 promotes androgen-dependent prostate cancer survival. Mol cell biol. 2012;32(2):399-414.
34. Rajan P, et al. Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy. Eur urol. 2014;66(1):32-9.
35. Sharma A, et al. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J clin invest. 2010;120(12):4478-92.
36. Akamatsu S, et al. The placental gene peg10 promotes progression of neuroendocrine prostate cancer. Cell rep. 2015;12(6):922-36.
37. Palm K, Metsis M, Timmusk T. Neuron-specific splicing of zinc finger transcription factor rest/nrsf/xbr is frequent in neuroblastomas and conserved in human, mouse and rat. Brain res mol brain res. 1999;72(1):30-9.
38. Shimojo M, et al. The small cell lung cancer-specific isoform of re1-silencing transcription factor (rest) is regulated by neural-specific ser/arg repeat-related protein of 100 kda (nsr100). Mol Cancer Res. 2013;11(10):1258-68.
39. Greytak SR, et al. Accuracy of molecular data generated with ffpe biospecimens: lessons from the literature. Cancer Res. 2015;75(8):1541-7.
40. Yang W, et al. Direct quantification of gene expression in homogenates of formalin-fixed, paraffin-embedded tissues. Biotechniques. 2006;40(4):481-6.
41. Hughey JJ, Butte AJ. Robust meta-analysis of gene expression using the elastic net. Nucleic acids res. 2015;43(12):E79.
42. Helpap B, Kollermann J, Oehler U. Neuroendocrine differentiation in prostatic carcinomas: histogenesis, biology, clinical relevance, and future therapeutical perspectives. Urol int. 1999;62(3):133-8.
43. Kleb B, et al. Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas. Epigenetics. 2016;11(3):184-93.
44. Ku SY, et al. Rb1 and trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science. 2017;355(6320):78-83.
45. Mu P, et al. Sox2 promotes lineage plasticity and antiandrogen resistance in tp53- and rb1-deficient prostate cancer. Science. 2017;355(6320):84-8.